NCT07675525Completed
Deep Learning for Liver Fibrosis Triage in MASLD Using Longitudinal Electronic Health Records
NIMIT-AI: Neural Inference for Metabolic-liver Integrated Trajectories: Leveraging Deep Learning to Enhance Reliability in MASLD Triage
Source: ClinicalTrials.gov · Last updated 30 Jun 2026
Brief summary (registry, in English)
This study looks at a new computer program called NIMIT-AI (Neural Inference for Metabolic-liver Integrated Trajectories, Artificial Intelligence) that helps doctors find liver scarring early in patients with fatty liver disease. Fatty liver disease, also called metabolic dysfunction-associated steatotic liver disease (MASLD), is a common condition where fat builds up in the liver. Over time, this can cause scarring (fibrosis). Finding scarring early helps doctors treat it before it gets worse. Right now, doctors use a blood test score called FIB-4 to check for scarring. But this score misses many patients and cannot be calculated when blood test results are incomplete. NIMIT-AI works differently. It reads a patient's blood test results over multiple visits, not just one visit, to spot patterns that suggest liver scarring. It was tested on 969 patients seen at Siriraj Hospital in Bangkok, Thailand between 2018 and 2022. In testing, NIMIT-AI found liver scarring more accurately than FIB-4. It also worked even when some blood test results were missing, which happens often in real clinics. This study did not ask patients to do anything extra. It used health records that were already collected as part of regular care.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 1351 (actual)
- First submitted
- 18 Jun 2026
- Start date
- 1 Jan 2018
- Primary completion date
- 31 Dec 2022
- Lead sponsor
- Siriraj Hospital
- Diseases
- Fatty liver disease (MASLD/MASH)
- NCT number
- NCT07675525
What you commit to
- Study type: Observational
- Participants enrolled: 1351
- From 1 Jan 2018 to the primary completion date, 31 Dec 2022
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior liver transplantation
Other illness
- Alternative chronic liver disease aetiology (autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, Wilson's disease, haemochromatosis)
- Chronic viral hepatitis (hepatitis B or C surface antigen positivity)
- Active extrahepatic malignancy at baseline
Other
- Insufficient longitudinal data for outcome ascertainment
Who the study is looking for
- Age ≥18 years at index visit
- Confirmed MASLD diagnosis per Delphi consensus criteria
- At least one outpatient visit with concurrent laboratory data and FibroScan liver stiffness measurement within observation window (2018-2022)
- Receiving care at Division of Gastroenterology, Faculty of Medicine Siriraj Hospital, Mahidol University
Age in the registry: 18 years to - · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Faculty of Medicine Siriraj Hospital Coordinator of this site? Confirm its status | Bangkok Noi | Thailand | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.